This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About DermTech Stock (NASDAQ:DMTK) 30 days 90 days 365 days Advanced Chart Get DermTech alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.05▼$0.4252-Week Range N/AVolume3.66 million shsAverage Volume1.07 million shsMarket Capitalization$3.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. Read More Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Email Address DMTK Stock News HeadlinesDERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 10, 2025 | globenewswire.comNorth American Morning Briefing: TSMC Earnings -2-October 18, 2024 | morningstar.comMElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)DermTech, Inc. (DMTKQ)September 27, 2024 | finance.yahoo.comVictory RS Small Cap Growth ASeptember 8, 2024 | morningstar.comMWhy Is DermTech (DMTK) Stock Down 26% Today?June 24, 2024 | investorplace.comDermTech Files for Voluntary Chapter 11 ProtectionJune 18, 2024 | businesswire.comDMTK Stock Earnings: DermTech Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSee More Headlines DMTK Stock Analysis - Frequently Asked Questions How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.03. The business had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.40 million. DermTech had a negative net margin of 572.19% and a negative trailing twelve-month return on equity of 138.79%. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Digital Turbine (APPS), Datadog (DDOG) and Cloudflare (NET). Company Calendar Last Earnings11/09/2021Today7/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:DMTK CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$100.89 million Net Margins-572.19% Pretax Margin-572.19% Return on Equity-138.79% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.46 Sales & Book Value Annual Sales$15.66 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / BookN/AMiscellaneous Outstanding Shares34,963,000Free Float33,180,000Market Cap$3.29 million OptionableOptionable Beta2.48 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:DMTK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DermTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.